Litton Mark James 4/A
4/A · Athira Pharma, Inc. · Filed Oct 3, 2024
Insider Transaction Report
Form 4/AAmended
Litton Mark James
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-10-03+325,000→ 325,000 totalExercise: $0.43Exp: 2034-10-02→ Common Stock (325,000 underlying)
Footnotes (2)
- [F1]The original Form 4 incorrectly reported the Exercise Price as $0.4499.
- [F2]One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.